VCE-004.3   Click here for help

GtoPdb Ligand ID: 10030

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: VCE-004.3 is a semi-synthetic cannabidiol quinone derivative [2]. It acts as a dual PPARγ/CB2 receptor agonist and CB1 receptor modulator. The structure is claimed in patent WO2015158381 [1]. VCE-004.3 is functional (promotes transactivation) on PPARγ via a binding site that is distinct from the canonical rosiglitazone binding site on this nuclear receptor.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 66.4
Molecular weight 413.29
XLogP 7.3
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCCNC1=C(CCCCC)C(=O)C(=O)C(=C1O)C1C=C(C)CCC1C(=C)C
Isomeric SMILES CCCCCNC1=C(CCCCC)C(=O)C(=O)C(=C1O)[C@@H]1C=C(C)CC[C@H]1C(=C)C
InChI InChI=1S/C26H39NO3/c1-6-8-10-12-20-23(27-15-11-9-7-2)25(29)22(26(30)24(20)28)21-16-18(5)13-14-19(21)17(3)4/h16,19,21,27,29H,3,6-15H2,1-2,4-5H3/t19-,21+/m0/s1
InChI Key CIEWIZBPWBLHSB-PZJWPPBQSA-N
Immunopharmacology Comments
VCE-004.3 exhibits anti-inflammatory and anti-fibrotic efficacy in in vivo models of systemic sclerosis (scleroderma) [2].